1
|
Evans R, Kimura H, Nakashima M, Ishikawa T, Yukitake H, Suzuki M, Hazel J, Faessel H, Wu J, Hang Y, Alexander R, Rosen L, Hartman DS, Ratti E. Orexin 2 receptor-selective agonist danavorexton (TAK-925) promotes wakefulness in non-human primates and healthy individuals. J Sleep Res 2023; 32:e13878. [PMID: 36934366 DOI: 10.1111/jsr.13878] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2022] [Revised: 02/24/2023] [Accepted: 02/28/2023] [Indexed: 03/20/2023]
Abstract
The orexin 2 receptor-selective agonist danavorexton (TAK-925) has been shown to produce wake-promoting effects in wild-type mice, narcolepsy-model mice, and individuals with narcolepsy type 1 and type 2. Here, we report wake-promoting effects of danavorexton in non-human primates and healthy men during their sleep phase. Electroencephalogram analyses revealed that subcutaneous administration of danavorexton significantly increased wakefulness in common marmosets (p < 0.05 at 0.1 mg kg-1 , and p < 0.001 at 1 mg kg-1 and 10 mg kg-1 ) and cynomolgus monkeys (p ≤ 0.05 at 1 mg kg-1 and 3 mg kg-1 ). In a phase 1b crossover, randomized, double-blind, placebo-controlled and active-controlled study in sleep-deprived healthy participants (ClinicalTrials.gov identifier: NCT03522506), modafinil 300 mg (used to demonstrate assay sensitivity) and continuous infusion of danavorexton 44 mg and danavorexton 112 mg showed statistically superior wake-promoting effects to placebo (n = 18). Measured using the Maintenance of Wakefulness Test, mean (standard deviation) sleep latencies during infusion of danavorexton 44 mg, danavorexton 112 mg and placebo were 21.4 (8.9), 31.8 (3.2) and 9.2 (6.4) min, respectively. Least-squares mean difference from placebo in average sleep latency was 16.8 min with danavorexton 44 mg and 30.2 min with danavorexton 112 mg (both p < 0.001). Karolinska Sleepiness Scale scores were statistically significantly lower (indicating decreased sleepiness) for participants receiving danavorexton than for those receiving placebo during infusion (danavorexton 44 mg, p = 0.010; danavorexton 112 mg, p < 0.001). Together, these results indicate that an orexin 2 receptor agonist increases wakefulness in non-human primates and healthy individuals during their sleep phase.
Collapse
Affiliation(s)
- Rebecca Evans
- Neuroscience Therapeutic Area Unit, Takeda Development Center Americas, Inc., Cambridge, Massachusetts, USA
| | - Haruhide Kimura
- Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
| | - Masato Nakashima
- Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
| | - Takashi Ishikawa
- Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
| | - Hiroshi Yukitake
- Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
| | - Motohisa Suzuki
- Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
| | - James Hazel
- Neuroscience Therapeutic Area Unit, Takeda Development Center Americas, Inc., Cambridge, Massachusetts, USA
| | - Hélène Faessel
- Neuroscience Therapeutic Area Unit, Takeda Development Center Americas, Inc., Cambridge, Massachusetts, USA
| | - Jingtao Wu
- Neuroscience Therapeutic Area Unit, Takeda Development Center Americas, Inc., Cambridge, Massachusetts, USA
| | - Yaming Hang
- Neuroscience Therapeutic Area Unit, Takeda Development Center Americas, Inc., Cambridge, Massachusetts, USA
| | - Robert Alexander
- Neuroscience Therapeutic Area Unit, Takeda Development Center Americas, Inc., Cambridge, Massachusetts, USA
| | - Laura Rosen
- Neuroscience Therapeutic Area Unit, Takeda Development Center Americas, Inc., Cambridge, Massachusetts, USA
| | - Deborah S Hartman
- Neuroscience Therapeutic Area Unit, Takeda Development Center Americas, Inc., Cambridge, Massachusetts, USA
| | - Emiliangelo Ratti
- Neuroscience Therapeutic Area Unit, Takeda Development Center Americas, Inc., Cambridge, Massachusetts, USA
| |
Collapse
|